Effect of Bevacizumab on Survival and Production of Nitric Oxide in Trabecular Meshwork Cells.
10.3341/jkos.2009.50.9.1404
- Author:
Sin Hoo KIM
1
;
Jae Woo KIM
Author Information
1. Department of Ophthalmology, Catholic University of Daegu College of Medicine, Daegu, Korea. jwkim@cu.ac.kr
- Publication Type:Original Article
- Keywords:
Bevacizumab;
Nitric oxide;
Trabecular meshwork cells
- MeSH:
Antibodies, Monoclonal, Humanized;
Humans;
Nitric Oxide;
Trabecular Meshwork;
Vascular Endothelial Growth Factor A;
Bevacizumab
- From:Journal of the Korean Ophthalmological Society
2009;50(9):1404-1408
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To investigate the effect of bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), on the survival and production of nitric oxide (NO) in human trabecular meshwork cells (HTMC). METHODS: Primarily cultured HTMC were exposed to 0, 0.25, 1.0, and 2.5 mg/ml bevacizumab for 24 hours. Cellular survival and production of NO were assessed by MTT assay and Griess assay, respectively. RESULTS: Bevacizumab did not affect the cellular survival at low concentrations but decreased cellular survival significantly at high concentrations (>1.0 mg/ml) accompanied with increased NO production. CONCLUSIONS: High concentrations of bevacizumab may be toxic to HTMC.
